- Home
- AQST vs MGTX Comparison
AQST vs MGTX Comparison
Compare AQST & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AQST | MGTX |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 707.6M | 665.7M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | AQST | MGTX |
|---|---|---|
| Price | $2.95 | $7.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $8.83 | ★ $23.83 |
| AVG Volume (30 Days) | ★ 6.4M | 420.4K |
| Earning Date | 03-04-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $43,397,000.00 | $27,417,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $43.02 | $567.62 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 96.83 |
| 52 Week Low | $2.12 | $4.55 |
| 52 Week High | $7.55 | $9.73 |
Technical Indicators
Market Signals| Indicator | AQST | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 23.93 | 46.02 |
| Support Level | $3.17 | $7.72 |
| Resistance Level | $3.55 | $8.17 |
| Average True Range (ATR) | 0.25 | 0.38 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 2.06 | 45.36 |
Price Performance
Historical ComparisonAbout AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.